Company intelligence / Profile preview

China Regenerative Medicine International

Hong Kong (Tsim Sha Tsui, Suite 2310-2318 Miramar Tower, 132 Nathan Road), Hong Kong

Ownership: Private
Employees: ~35
Development stage: Other

Overview

CRMI has commercialized tissue engineered skin (ActivSkin) and bio-engineering cornea (Acornea). ActivSkin is noted as the only tissue-engineered skin with living cells in China, while Acornea is described as the world's first bio-engineering cornea.

Therapeutic areas: OtherOphthalmologyDermatology
Modalities: Cell therapyTissue engineeringGene therapyStem cell therapy
Industry: Biotech

Partnerships

University of Oxford (CRMI Technology Centre)Mila D'Opiz Group (Switzerland)

Beyond the preview

Go deeper on China Regenerative Medicine International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China Regenerative Medicine International.

Explore the full profile